Provide feedbackProvide feedback

Home :: Pulmonary/Respiratory

Elevation Pharmaceuticals' investigational COPD therapy meets primary endpoint of Phase IIb trial

Wednesday, May 16 2012 | Comments
Evidence Grade 0 What's This?

Elevation Pharmaceuticals Inc.'s EP-101, an investigational once-daily inhalation solution formulation of glycopyrrolate, significantly improves lung function in patients with moderate to severe chronic obstructive pulmonary disease (COPD), according to data from a Phase IIb trial. The GOLDEN-1 trial was a double-blind, crossover study that included 140 patients aged 40 to 75 years with moderate to severe COPD. The study compared four doses of EP-101 with placebo and two open-label active...

Elevation Pharmaceuticals Inc.'s EP-101, an investigational once-daily inhalation solution formulation of glycopyrrolate, significantly improves lung function in patients with moderate to severe chronic obstructive pulmonary disease (COPD), according to data from a Phase IIb trial.

The GOLDEN-1 trial was a double-blind, crossover study that included 140 patients aged 40 to 75 years with moderate to severe COPD. The study compared four doses of EP-101 with placebo and two open-label active controls--Pfizer Inc. and Boehringer Ingelheim Pharmaceuticals Inc.'s Spiriva (tiotropium bromide monohydrate) inhalation powder and ipratropium bromide inhalation solution.

EP-101 and placebo were administered once daily using Pari Pharma GmbH's investigational handheld eFlow nebulizer device, Spiriva (18 mcg once daily) was administered with the Spiriva HandiHaler dry-powder inhaler and ipratropium bromide (500 mcg three times per day) was administered with a general purpose nebulizer.

All four doses of EP-101 met the primary endpoint of the trial, demonstrating superior improvements in lung function (assessed with 24-hour trough forced expiratory volume in one second) relative to placebo after seven days of treatment.

Elevation said that the complete results of the GOLDEN-1 trial will be presented at an upcoming medical conference. The firm is planning to initiate a second Phase IIb study in the fourth quarter to select the optimal dose of EP-101 for a pivotal Phase III program.

EP-101's active ingredient, glycopyrrolate, is a long-acting muscarinic antagonist. Elevation licensed the eFlow nebulizer device from Pari Pharma. The nebulizer was optimized specifically for EP-101 and enables "highly efficient" aerosolization of medications via a vibrating, perforated membrane, Elevation said, adding that this technology produces aerosols with a very high density of active drug, a precise droplet size and a high proportion of respirable droplets delivered in the shortest period of time.

This information concerns a use that has not been approved by the Food and Drug Administration.

Latest News

Novavax initiates second early-stage trial of bird flu vaccine candidate Verusmed

Thursday, May 10 2012 | Comments
Evidence Grade 0 What's This?

Novavax Inc. started a second Phase I study of its monovalent virus-like particle (VLP) vaccine candidate to prevent potential pandemic disease stemming from A/H5N1 avian influenza viruses. 

The purpose of the randomized, observer-blinded, dose-ranging trial is to evaluate the safety of the VLP A/H5N1 avian flu vaccine candidate and determine its immunogenicity with and without the use of an adjuvant. The...



Vertex reports potential CF drug combination significantly improves lung function; shares rise Verusmed

Monday, May 07 2012 | Comments
Evidence Grade 0 What's This?

Vertex Pharmaceuticals Inc.'s VX-809, an investigational treatment for cystic fibrosis (CF), provided significant improvements in lung function in a recent midstage study when administered in combination with Vertex's Kalydeco (ivacaftor), which just gained Food and Drug Administration approval in January for certain patients with CF.

Shares of Vertex soared 55.4 percent...



FDA lifts hold on second trial of Insmed's Arikace Verusmed

Monday, May 07 2012 | Comments
Evidence Grade 0 What's This?

Insmed Inc. said the Food and Drug Administration lifted the clinical hold previously placed on a Phase III trial investigating Arikace (liposomal amikacin) for inhalation in patients with cystic fibrosis (CF) who have Pseudomonas lung infections.

The FDA and Insmed agreed on a revised CF clinical trial population that includes adults who have chronic Pseudomonas lung...



Meda's Dymista approved as treatment for seasonal allergy symptoms Verusmed

Wednesday, May 02 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration approved Meda AB's Dymista (fluticasone propionate/azelastine hydrochloride) nasal spray for the treatment of seasonal allergic rhinitis (SAR).

Specifically, the spray, which is administered twice-daily in each nostril, is approved for the relief of SAR symptoms in patients aged 12 years or older who require treatment with both of...





  1. No articles have been read
  1. No articles have been emailed
Videos